

-GastroPanel test and Type 1 Diabetes-

**Biohit *GastroPanel® test in Screening of the Patients with
Type 1 Diabetes Mellitus (DM1) for Autoimmune Atrophic Gastritis (AAG)**

Jointly Executed by:

Hospital X (City Y);
Biohit Oyj (Helsinki)

Research Team:

A B, B C, C D, Lea Paloheimo, Panu Hendolin, Carita Eklund, Kari Syrjänen

*The new **Unified GastroPanel®** test: ELISA biomarker test for pepsinogen I (P-PGI), pepsinogen II (P-PGII), gastrin-17 (P-G-17), and *H.pylori* IgG antibodies (P-HpAb).

Summary

Background: Autoimmune gastritis and pernicious anemia (PA) are common autoimmune disorders, being present in up to 2% of the general population. However, in patients with type 1 diabetes (DM1) or autoimmune thyroid disease, the prevalence is 3- to 5-fold. Autoimmune atrophic gastritis (AAG) is characterized by: 1) atrophy of the corpus and fundus; 2) autoantibodies to the parietal cell (PC) and to the intrinsic factor (IF); 3) achlorhydria; 4) iron deficiency anemia; 5) hypergastrinemia; 6) vitamin-B12 deficiency leading to PA; 7) in up to 10% of the patients, AAG may predispose to gastric cancer (GC) or carcinoid tumours. In addition to autoimmune disease, *Helicobacter pylori* (HP)-infection is the other important causative agent of atrophic gastritis (AG), and now suspected to be **a trigger of AAG** as well.

The high prevalence of AAG in DM1 and its potentially serious consequences provide **a strong rationale for screening**, early diagnosis, periodic surveillance by gastroscopy, and treatment. Whether regular **gastroscopic** surveillance is needed in patients with AAG/PA is **controversial**. To obviate the need for invasive diagnostic methods (gastroscopy) for these conditions, Biohit Oyj (Helsinki, Finland) launched several years ago an ELISA-based assay designed to measure the concentrations of four stomach-specific biomarkers (Pepsinogen I, Pepsinogen II, Gastrin-17, *H. pylori* IgG antibodies) from a single blood sample. This GastroPanel® test is **the first non-invasive** diagnostic tool for stomach health (testing both the structure and function). The new-generation **Unified GastroPanel®** is a technically advanced version of this test, where the processing conditions of all biomarkers are uniform, making the test more versatile.

Objective: To conduct a systematic GastroPanel® screening of DM1 patients to establish the **prevalence of AAG** and its associated risks (PA included). Another objective is to assess the utility of this non-invasive serum biomarker test as **a substitute to gastroscopy** in the **systematic monitoring** of the DM1 patients for AAG and its severe clinical sequels.

Study Design: This study is a targeted screening trial for asymptomatic and symptomatic DM1 patients. A cohort of patients with prevalent DM1 (newly diagnosed cases excluded) are subjected to screening by the Unified GastroPanel® test. The result is classified as one of the optional diagnostic categories: 1) healthy stomach, 2) superficial HP-gastritis, 3) AG of the antrum; 4) AG of the corpus, and 5) AG of the antrum and corpus (pan-gastritis). AG patients testing HP-negative are likely to represent AAG. All patients with GastroPanel® result suggesting AG/AAG will be referred for gastroscopy and biopsy confirmation used as gold standard.

Methods: Study subjects (above 45 years of age, both genders) are enrolled among the DM1 patients controlled in the outpatient department for diabetics at Hospital X. All eligible patients who consent to participate will be invited for blood sampling for GastroPanel® testing, instructed to be compliant with the patient preparation. All blood samples will be stored at -70C until delivered for analysis in the laboratory of Biohit Oyj (Helsinki). On the occasion of blood sampling, all patients fill in questions from **validated questionnaires** exploring possible dyspeptic symptoms and potential sequels of AAG. Patients with suggested AG/AAG in the GastroPanel® test will be referred to gastroscopic examination, with directed gastric biopsies, following the protocol of the Updated Sydney System (USS). Statistical analyses include calculation of the performance indicators of the GastroPanel® test for individual study endpoints, including ROC analysis for the optimal sensitivity/specificity balance, using moderate/severe AG/AAG as the endpoint.

Specific Aims: The main goal of this screening trial is to establish **the prevalence of AGG** among the patients with prevalent DM1. Related to the assessment of the validity of GastroPanel in systematic surveillance of DM1 patients, three clinically relevant issues need to be addressed: 1) the **rate of unnecessary referrals** for gastroscopy (false positive rate; 1-PPV) following a positive GastroPanel® test; 2) the **rate of gastroscopies to be avoided** after a negative GastroPanel® examination (true negative rate; NPV), and 3) the rate of clinically **significant diseases** (conditions) that are **missed** by the GastroPanel® examination (i.e., false negative rate; 1-SE).

Study execution and time table: The study plan necessitates a review by the regional review board (Hospital X, Ethical Committee) before start. Given that the subjects in the study will be enrolled among DM1 patients attending the outpatient department of Hospital X (other sites?), it is estimated that the screening of a cohort of 1000 patients will take approximately ? months. It is estimated that a cohort of 100-150 subjects (enriched by all grades of AG/AAG) should be enough to give this GastroPanel® study the necessary statistical power.

Impact of the study: The known high prevalence of AAG in DM1 and its potentially severe clinical sequels advocate 1) screening, 2) early diagnosis, 3) regular surveillance, and 4) treatment. However, it is still **controversial**, whether **regular gastroscopic surveillance** is needed for DM1 patients with AAG/PA. The present study will provide new insights i) in the true prevalence of AAG among the DM1 patients, as well as ii) on the utility of the **non-invasive biomarker** test (GastroPanel®) as a substitute of gastroscopy in the systematic **surveillance** of DM1 patients for AAG.

1.BACKGROUND

Autoimmune atrophic gastritis (AAG) and pernicious anemia (PA) are common autoimmune diseases with respective prevalence of 2% and 0.15–1% in the general population, increasing with age (1,23). In patients with type 1 diabetes (DM1) (4, 5) or autoimmune thyroid disease (6, 7), the prevalence is 3- to 5-fold increased. AAG is characterized by atrophy of the corpus and fundus, and the presence of circulating autoantibodies to the parietal cell (PCA) and to their secretory product, intrinsic factor (IF) (8). Chronic auto-aggression to the gastric proton pump, H⁺/K⁺ATPase, may result in decreased gastric acid secretion, hypergastrinemia, and iron deficiency anemia (9, 10). In a later stage of the disease, PA may result from vitamin-B12 deficiency, which is 10 times more common in DM1 patients than in non-diabetic subjects (5). Finally, in up to 10% of patients, AAG may predispose to gastric carcinoid tumors or adenocarcinomas (11-17). Determining demographic, immunological, and genetic risk factors, and early diagnosis of AAG are important to prevent and treat iron deficiency anemia, PA, and (pre)malignant gastric lesions: intestinal metaplasia (IM) and enterochromaffin-like cell (ECL) hyper/dysplasia (5).

1.1.Definition of autoimmune atrophic gastritis (AAG)

AAG affects the parietal cell-containing gastric corpus and fundus with sparing of the antrum (8, 18). PCA, targeted against gastric H⁺/K⁺ ATPase, are detected in 60–85% and IF antibodies in 30–50% of patients with AAG (5,19). Besides PA, iron deficiency anemia is frequently observed (9, 10). Furthermore, AAG is characterized by hypo- or achlorhydria, high serum gastrin, and low pepsinogen I concentrations (20,21). Chronic hypergastrinemia causes the ECL cells in the oxyntic mucosa to undergo hyperplasia (22), which may progress toward dysplasia and gastric carcinoid tumors (11, 21).

PCA are detected by immunofluorescence staining of the cytoplasm of gastric parietal cells (23). However, Karlsson et al. (24) showed that the ELISA to detect gastric H⁺/K⁺ ATPase antibodies is 10-fold more sensitive than the indirect immunofluorescence technique and has a high specificity. Current ELISAs have a sensitivity and specificity of respectively 85–93% and 80–85%. PCA are detected 60–90% of the patients with AAG and/or PA (1,8,23).

The recognition of antibodies to IF (AIF) derives from the work of Taylor et al. (25) and Schwartz (15). Two types of autoantibodies bind to IF. Type I AIFs block the binding of

vitamin-B12 to IF, thereby preventing the transport of vitamin-B12 from the stomach to its absorption site in the terminal ileum. Type I AIFs are demonstrable in 70% of the patients with PA (24). Type II AIFs do not interfere with vitamin-B12 transport. They can be found in 30–40% of patients with PA.

The destruction of H⁺/K⁺ATPase-containing parietal cells results in hypo- or achlorhydria. This can be measured using 24-h gastric pH-metry or after stimulation with pentagastrin. Hypochlorhydria is defined as a maximal acid output less than 15 mmol H⁺/h after injection of pentagastrin. A progressive decrease in acid secretion in the case of AAG with a decreased parietal cell mass has been found (21,26,27). Total achlorhydria is diagnostic of PA. Achlorhydria interrupts the negative feedback of somatostatin on antral gastrin-producing G cells causing hypergastrinemia (28). Fasting serum gastrin (G-17) levels correlate negatively with peak acid output, and positively with the degree of corpus atrophy (21, 29) and with PCA levels (21). Low serum pepsinogen I levels, resulting from destruction of chief cells or zymogenic cells, are also characteristic to AAG (20,30,31).

1.2. Endoscopy and Pathology of AAG

On endoscopy, the affected corpus and fundus mucosa appears shiny and red because of the visibility of submucosal blood vessels. The stomach wall is thinned, and the rugal folds flatten or disappear. In biopsy specimens, lymphocytic infiltrates are present in the submucosa and lamina propria (19,21). In the next stage, there is a marked reduction in the number of oxyntic glands, parietal and zymogenic cells, followed by replacement of normal glands by glandular structures lined with mucus-containing cells resembling those of the small bowel mucosa (intestinal metaplasia, IM). A proliferation of ECL cells in the oxyntic mucosa (22), due to sustained hypergastrinemia, can be seen, which may progress in a small proportion of patients toward carcinoid tumors (11,32,33,34).

1.3. Epidemiology of AAG

In the general population, there is an age-related increase in the prevalence of parietal cell antibodies (PCA), from 2.5% in the third decade to 12% in the eighth decade (1,2). The prevalence is even higher in subjects affected by another autoimmune disorder. In DM1, PCAs are found in 10–15% of the children and in 15–25% of the adults (4,5,35,36,37). The respective prevalence of AAG and PA in the general population are 2% and 0.15–1% (2,3,38,

39), compared with 5–10% and 2.6–4%, respectively, in DM1 patients (5,21,38,40,41). Iron deficiency anemia is present in 20–40% of patients with AAG (10, 42), whereas PA can be diagnosed in up to 15–25% of the patients (43). The progression of AAG to PA is likely to span 20–30 years (44).

Finally, gastric carcinoid tumors are observed in 4–9% of the patients with AAG/PA, which is 13 times more frequent than in controls (11,32,33,34,45). Patients with AAG/PA also have a 3- to 6-fold increased risk of GC, ranging from 0.9–9% (11,32,34,46,47,48).

1.4.Pathogenesis of AAG

The target autoantigens in AAG are the 100-kd catalytic α -subunit and the 60- to 90-kd glycoprotein β -subunit of the gastric H⁺/K⁺ATPase (49, 50). **Autoantibodies to parietal cells (PCA)** and to their secretory product, IF, are present in the serum and in gastric juice. The titer of PCAs correlates with the severity of corpus atrophy and is inversely proportional to the concentration of parietal cells (21, 29). CD4⁺T-cells recognizing parietal cell H⁺/K⁺ATPase mediate autoimmune gastritis. During normal cell turnover, PCs release H⁺/K⁺ATPase, which may result in its selective uptake and processing by antigen-presenting cells (51).

Alternatively, *Helicobacter pylori* (HP)-infection may play **an initiating role** in the pathogenesis of AAG and PA (52,53,54,55) by inducing autoreactive T-cells through gastric H⁺/K⁺ATPase-HP molecular mimicry at the T-cell level (53,54), epitope spreading, and bystander activation. B-cells produce autoantibodies to gastric H⁺/K⁺ATPase and to their secretory product, IF, with help from activated CD4⁺T-cells (50). Finally, PC loss from the gastric mucosa may result from CD4⁺ T-cells initiated perforin-mediated cytotoxicity or Fas-FasL apoptosis (55).

Regardless of whether PCAs are pathogenic or not, their presence provides a convenient diagnostic probe for AAG. A precise understanding of the pathogenesis of autoimmunity may lead to rational therapeutic strategies directed toward restoration of tolerance or impeding the progression of autoimmunity. Whether HP could trigger AAG or not remains controversial (5). However, should this be the case, HP eradication might be able to prevent AAG. Currently,

it is recommended that HP-infection should be tested and treated in patients with gastric atrophy, intestinal metaplasia/dysplasia, and hypo- or achlorhydria (5).

1.5.Demographic factors

Advancing age is a risk factor that has been associated with PCA positivity (5). In the general population, PCA positivity increases from 2.5% in the third decade to 12% in the eighth decade (1,2). In DM1 patients, PCA are present in 10–15% of the children and 15–25% of the adults (41). Some authors (4,35) report a female preponderance for PCA positivity, although this has not been consistently confirmed in other studies (37,41).

1.6.Endocrine factors

AAG is frequently accompanied by other autoimmune diseases, including DM1 (5) and autoimmune thyroid disease (Hashimoto's thyroiditis and Graves' disease) (6,38,56). AAG is also part of the **autoimmune polyglandular syndrome type 3 (PGA3)**(57). PA occurs in up to 4% of DM1 patients (5, 40), 2–12% of patients with autoimmune thyroid disease (6, 58), 6% of those with Addison's disease, 9% of those with primary hypoparathyroidism, and 3–8% of those with vitiligo (1,5).

In patients with DM1, immunological risk factors that have been associated with PCA positivity include persistent islet cell antibody positivity (35,36), glutamic acid decarboxylase-65 antibody positivity (41,59), and thyroid peroxidase autoantibody positivity (41,59). The association with glutamic acid decarboxylase-65 antibodies might be explained by the fact that glutamate decarboxylase-65 is not only present in the pancreas and brain but can also be found in the thyroid gland and stomach. PCA are more frequent in DM1 patients than in their first-degree relatives, even after HLA matching, suggesting that the diabetic condition itself plays an important role (60). The association of AAG/PA with the other autoimmune disease falls outside the scope of this text (5).

1.7.Environmental factors

Helicobacter pylori (HP) might be implicated in the induction of AAG (52,53,55). This hypothesis is supported by studies reporting a high prevalence of HP-seropositivity and a low prevalence of positive HP-staining in subjects with atrophic corpus gastritis (61,62,63,64). Furthermore, the finding of gastric autoantibodies in 20–50% of HP-infected patients and

reports of a positive correlation between gastric autoantibodies and antibodies to HP in patients with AAG/PA (63,65,66,67,68) suggest that chronic HP-infection is linked with gastric autoimmunity. However, a correlation between HP and PCAs has not been reported in all studies (39,69,70). Moreover, others found no or a negative link between HP and atrophic corpus gastritis (71). On the other hand, HP eradication in patients who have antigastric antibodies leads to the loss of those antibodies in some subjects (72). These data revisit the concept of possible reversibility of gastric mucosa atrophy (5).

1.8. Monitoring the patients at risk for AAG and its sequels

AG/AAG is the single most powerful independent risk factor for distal (non-cardia) GC (73,74,75,76). It is estimated that 50% of all GC cases develop through the “Correa cascade” (74,77,78,79), leading from HP-associated- or autoimmune gastritis to mucosal atrophy, intestinal metaplasia, dysplasia, and to invasive adenocarcinoma. There are some implications that early eradication of HP-infection can slow down or even revert this cascade (80,81). Because this process takes several decades, there should be good prospects for early detection of precancerous lesions (82), but the problem is lack of a suitable test for GC screening (83). Furthermore, most of the patients report only a short period of symptoms before the diagnosis of GC, and up to 40% report no dyspeptic symptoms at all (84).

It is **controversial** whether patients with AAG/PA should be placed under a surveillance program with **regular gastroscopies**, including multiple gastric biopsies (5). The gastric carcinoids that occur in these patients generally do not pose a great threat to life, whereas the risk of developing GC is real. Nevertheless, in many clinics, endoscopy with biopsies remains the gold standard diagnostic tool, disclosing HP-infection, mucosal atrophy, intestinal metaplasia or dysplasia, and their topography (73,85) However, this invasive method is uncomfortable, distressing and quite costly, emphasizing the need for rapid, reliable and inexpensive non-invasive tests for screening and monitoring these patients(83,84,86).

1.8.1. Non-invasive diagnostic tools for monitoring

Such non-invasive methods providing information on the structure and function of gastric mucosa were introduced in the early 1980's, when Miki et al. (87) and Samloff et al. (88) developed assays measuring pepsinogen (PG) concentrations in the blood. The latest development in this field represents the panel combining serum pepsinogen I (PGI) and II

(PGII), gastrin-17 (G-17) and HP IgG antibodies (IgG-HP) using ELISA technique (GastroPanel® test, Biohit Oyj, Helsinki), proposed as the first-line diagnostic test for dyspeptic symptoms (89,90,91). According to a recent meta-analysis, serum PGs are not suitable for GC screening, however, but they proved to be useful for detecting the patients at risk for GC (92). Recently, these stomach-specific biomarkers were recommended by an authoritative international group of experts for diagnosis and screening of AG (93).

The GastroPanel test is based on combined analysis of PG-I, PG-II, amidated G-17 and HP-antibodies, designed to give information on both the structure and function of the stomach mucosa. Most importantly, this panel gives accurate estimates of the capacity of the corpus and antrum mucosa to secrete acid and G-17, respectively, as well as of important gastric pathologies like inflammation, grade and topography of AG (91,99,100,101). Normal plasma levels of these biomarkers indicate that the stomach mucosa has normal structure and function, whereas the abnormal levels are signs of a non-healthy stomach, reflecting the disturbances in the feedback mechanisms between the acid output, PGs and G-17 (102).

GastroPanel test has been on the market for several years by now, and during this time, it has been validated in clinical studies in Finland and elsewhere (95,96,103,104). Due to the inherent characteristics of the natural history of AG/AAG, the PGI values (and PGI/PGII ratio) remain within normal range as long as AG of the corpus is graded only as mild by the USS. However, mild AG/AAG is a poorly reproducible diagnostic category even among experienced pathologists, and because of this, mild AG of the corpus should never be used as the study endpoint in calculating the performance indicators of the PGI, PGI/PGII, as repeatedly emphasized (103,104,105). The only appropriate way of calculating the predictive indicators of PGI and PGI/PGII ratio for AG of the corpus is to use the combined moderate/severe AG as the study endpoint. Using this approach in an adequately powered study with validated USS classification gives ROC (AUC) values above 0.970 for PGI and >0.950 for the PGI/PGII ratio as predictors of moderate/severe AG of the corpus (103,105).

2.THE GASTROPANEL® TEST

The GastroPanel® is a user-friendly ELISA technique, intended both for research purposes and for clinical practice. The GastroPanel® test contains four biomarkers specific for the stomach mucosa: 1) Pepsinogen I (P-PGI), 2) Pepsinogen II (P-PGII), 3) Gastrin-17 (P-G-17)

and 4) *H. pylori* antibody (P-HpAb) (89,90,91).

2.1.ELISA test for Pepsinogen I and Pepsinogen II

P-PGI is secreted solely by the chief cells (chief cell/mucous neck cells) of the corpus mucosa. AG of the corpus leads to loss of these cells and, as a result, the P-PGI level in circulation decreases. P-PGII is produced by the chief cells and mucous neck cells of the gastric mucosa, by pyloric glands in the gastric antrum and by Brunner's glands in the proximal duodenum. The ratio of PGI to PGII concentration in the plasma of normal subjects is above 3.0.

2.2.ELISA test for Gastrin-17

The P-G-17 ELISA method in the GastroPanel® is specific to amidated G-17 molecule. G-17 peptide is the most important member of the gastrin/cholecystokinin-family which regulates the physiology of the upper gastrointestinal tract. This peptide is the biologically most active gastrin peptide, stimulating gastric acid secretion with 6-times higher potency than the biologically next most active gastrin, G-34. The G-17 ELISA in GastroPanel® assay allows estimation of the number and function of antral G-cells, without background noise and cross-reactivity with other gastrin fragments. G-17 is secreted exclusively by the gastrin-cells (G-cells) in the antrum, representing a fraction of the total gastrin concentration in the circulation. When dormant, the G-cells in antrum secrete only small amounts of G-17 hormone. The maximal secretion is achieved after physiological protein stimulation, or when the acid secretion in the stomach decreases, is low or absent. As a result of antral atrophy (i.e., loss of glands), the amount of G-cells decreases and, consequently, both the basal and post-prandial secretion of G-17 will decrease.

2.3.ELISA test for Helicobacter pylori (HpAb ELISA)

The *H. pylori* infection is the most important cause of chronic gastritis. Another well-known cause for severe AG is the autoimmune mechanism, which can also be activated by *H. pylori* infection (52,53,54,55). GastroPanel® test for *H. pylori* is performed from the plasma samples. The test is based on an ELISA technique, with purified *H. pylori* bacterial antigen, adsorbed on a microplate, and a detection antibody labeled with horseradish peroxidase (HRP).

2.4.The new unified GastroPanel® test

Prompted by the design of the original GastroPanel itself, where all four biomarkers are being

processed under different laboratory (incubation) conditions, Biohit R&D Department started a project towards unified GastroPanel® test in 2013. The concept was to develop a new assay, where all four markers are being processed under the same conditions using an automatic ELISA instrument or manual processing. The new Unified GastroPanel® test contains the same four markers as the current version (1.1), maintaining its basic design as an ELISA test. Because of the crucial modifications in the key test components, the unified test will be treated as a novel test by the registration authorities. Because of this fact, the new version must undergo all the necessary steps needed for CE registration, including clinical validation in a cohort of study subjects with relevant gastric pathologies.

3. STUDY DESIGN

The present study is designed as a targeted screening of patients with prevalent DM1, with or without signs of other autoimmune disease (I.E., PGA3), enrolled from the primary- and occupational health care. The cohort is screened by the Unified GastroPanel® test distinguishing 5 diagnostic categories: 1) healthy stomach, 2) HP-gastritis, 3) AG of the antrum, 4) AG of the corpus and 5) AG of both antrum and corpus. The test performance indicators will be calculated using moderate/severe AG/AAG as the endpoint, separately for markers of the antrum (G-17) and corpus (PGI, PGI/PGII ratio), respectively. As an additional endpoint, down-stream in the path to AG, is the detection of *H. pylori* infection in the antrum or in corpus.

3.1.Aims of the study

With the aid of a target screening, to establish the **true prevalence of AAG** among the patients with prevalent DM1, irrespective whether symptomatic or asymptomatic. Among DM1 patients, AAG can develop as a part of PGA3 syndrome or as solitary manifestation of autoimmune disease. Disclosing AAG as early as possible is important to be able to adopt adequate surveillance measures to prevent the serious clinical sequels of AAG in these patients.

Another aim is to demonstrate whether the currently **validated cut-off values** for the four biomarkers of GastroPanel (95,96,103,104,105) are applicable also for the atrophic gastritis developed through an autoimmune mechanism (AAG), apart from HP-associated AG. Given that GastroPanel® is a quantitative test, ROC analysis can be used to estimate the best SE/SP

balance for each single marker against the relevant endpoint to adjust the optimal clinical performance of the new GastroPanel® test.

Related to the applicability of GastroPanel test in the **systematic surveillance** of DM1 patients, three clinically relevant issues will be addressed in this **biopsy-confirmed** study: 1) the rate of unnecessary referrals for gastroscopy (false positive rate; 1-PPV) following a positive GastroPanel® test; 2) the rate of gastroscopies to be avoided after a negative GastroPanel® examination (true negative rate; NPV), and 3) the proportion of clinically significant diseases (conditions) that are missed by the GastroPanel® examination (i.e., false negative rate; 1-SE).

3.2. Patients

This targeted trial is conducted in collaboration between Hospital X (City Y) and the Clinical Research Department of Biohit Oyj (Helsinki). The clinical arm is performed exclusively by the Hospital, while the laboratory analyses will be done in the service laboratory of Biohit Oyj.

Enrolment of the patients in the study will take place exclusively at Hospital X, including consecutive patients over 45 years of age, attending their regular monitoring visit for DM1 at the outpatient department (ambulatory). The eligible patients can be asymptomatic or symptomatic (=dyspepsia), all having prevalent DM1 diagnosed years before. The estimated cohort to be screened for GastroPanel is at least 1000 subjects (both genders), to reach a cohort of 100-150 patients enriched with roughly **equal numbers of the relevant study endpoints** (different grades of AAG).

Patient enrollment is taking place in a single step. In brief, the potentially eligible patients are identified among the DM1 outpatients by the members of the research team. At this stage, every patient will be asked to consent the study and sign a written consent to participate. All consented patients will be interviewed using previously validated questionnaires (by the nurse administrator). They will be scheduled for an appointment to GastroPanel testing at the laboratory, to ensure compliance with the preparatory steps needed before the GastroPanel® sampling. Most importantly, apart from the recommended 10h fasting (overnight), the use of PPI-medication should be discontinued preferably one week before GastroPanel® sampling.

Eligible patients are all adults aging 45 years and above, irrespective whether symptomatic or asymptomatic as to their upper gastrointestinal tract. However, the following patients should be considered **non-eligible**: 1) the patients whose treatment requires surgery, or immediate follow-up treatment for major symptoms, as well as 2) those who refuse to sign the written consent.

3.2.1. Patient preparation

Reliable results from the GastroPanel® examination necessitate some preparatory measures of the patient. Detailed instructions are given to each test subject at the time of his/her consenting to participate. Questionnaires about the symptoms, diet, health information, socioeconomic status and compliance with the taking of medicines listed below must be controlled before taking the blood sample.

The patient should not drink, eat or smoke for at least 10 hours before the sample collection e.g. 10-hour fasting overnight is perfect. The patients are allowed to take their prescribed, regular medication, except for the following medicines that interfere with acid output:

- One week prior to sample collection: **H₂-receptor antagonists**; ranitidine (Esohex, Inside Brus, Ranicur, Ranil, Ranimex, Ranitidin, Ranitidine, Ranixal, Zantac), famotidine (Famotidin, Pepcid, Pepcidin, Pepcid Duo), nizatidine (Nizax); **proton pump inhibitors (PPI)**; lansoprazole, omeprazole, pantoprazole, esomeprazole, rabeprazole etc. (Lansoprazol, Lanzo, Zolt, Losec, Omeprazol, Nexium, Pariet, Somac, Gasterix, Pantoloc, Giasemin, Panzor).
- One day prior to sample collection: medication neutralizing gastric acid secretion: **antacids** (Balancid Novum, Gaviscon, Link, Magnesium milk, Novaluzid, Rennie) and mucosa protecting agents (Alsucral, Antepsin).

In any doubtful cases, the patient is advised to consult her/his physician about the discontinuation of the medication. In case that the medication (listed above) cannot be interrupted, the patient should give a detailed notice on the consumed medicines on the occasion of the GastroPanel sampling.

3.3. Methods

3.3.1. A GI-symptom questionnaire on i) functional dyspepsia and IBS according to the Rome III criteria and on ii) reflux disease symptoms according to the Montreal classification will be completed prior to blood sampling (106).

3.3.2. Sample collection for GastroPanel® test

The person taking the blood sample shall fill the test request (remittance) form. A minimum of 2 ml EDTA plasma from a fasting blood sample is taken into an EDTA tube (e.g. Biohit Cat. no. 454235 Vacuette 4ml tube containing K2EDTA). Use of G-17 stabilizer 100µl/2ml plasma (Biohit Cat. No. 601 050 or 601 051) allows a temporary storage of the sample at room temperature (20-25°C), before frozen.

3.3.3. Sample processing

The blood sample needs to be centrifuged within 30 minutes, at 1800-2000g for 10 minutes or as prescribed by tube manufacturer. Because not used for on-site testing, the EDTA plasma needs to be frozen instantly (-70°C). Using G-17 stabilizer enables a temporary storage in the refrigerator (at 2-8°C), for up to 3 days, but immediate freezing **at -70°C is the preferred method of storage. This is most critical for G-17, to avoid decay at too high temperature.**

Once the sampling has been completed, the frozen plasma samples will be delivered to the laboratory of Biohit Oyj (Helsinki) for analysis by GastroPanel test. All samples will be analysed in parallel using the current version of the GastroPanel test and the new unified GastroPanel test, following the instructions for use (IFU) of the test kits. The rest of the plasma samples will be stored at Biohit (-70C), to ensure eventual repeat analysis by GastroPanel (in case of technical failure or other need). The same bio-banked plasma samples can be tested later with other technical modifications of GastroPanel test, e.g. the Randox Chip GastroPanel test, currently on pipeline at Randox laboratories (Northern Ireland).

3.3.4. Stimulated G-17

Apart from the fasting sample, the study protocol also necessitates **another blood sample from all subjects**, following protein stimulation to analyse the level of stimulated G-17. The secretion of G-17 can be stimulated by the intake of a protein drink having average protein content of 77% [Biohit Cat. No. 601038 (50x20 g)]. This stimulation should not be performed

for patients who are sensitive to lactose (i.e., lactose intolerance or hypolactasia). To prepare the protein juice, 20g of protein (one foil bag of protein powder) is mixed to 150 ml of water. The stimulated blood sample must be taken 20 minutes after the intake of the protein juice.

3.3.5. Evaluation of GastroPanel® results

The results of the GastroPanel® test are evaluated using the GastroSoft® interpretation software. GastroPanel test is optimized for the Updated Sydney System (USS) for classification of gastritis, both including 5 diagnostic categories (see above for study endpoints). The test results will be delivered online to Hospital X, where the results are linked with the other clinical data of the patients, including the results of (upcoming) gastroscopy and biopsy histology.

3.4. Gastroscopy and biopsy procedures

In this screening study, all patients are examined with the GastroPanel® test first. Only those who test GastroPanel-positive, i.e., **the result is classified as AG/AAG**, will be subjected to gastroscopy. This provides the histological confirmation to be used as the gold standard in calculating the performance indicators for the test. Gastroscopy referrals will be made to the outpatient department of Gastroenterology, Hospital X (City Y). It is important that also the taking of gastric biopsies follows the same USS system, including biopsy sampling from the antrum and corpus as specified by USS (97,100,103). In endoscopy, all observed abnormal mucosal lesions are noted and photographed, and if necessary (e.g. suspicion of malignancy) subjected to additional biopsy. Endoscopic findings from the esophagus, stomach, duodenal bulb and the second part of the duodenum will be recorded according to a predefined protocol to improve consistency between the endoscopists. At the time of endoscopy, the endoscopists will be blinded to the questionnaires. The future management and surveillance of the patients will be arranged according to the normal practices of the clinic.

3.4.1. Biopsy protocols

The optimal use of the USS system necessitates that the biopsy protocol follows an agreed systematic. In each patient, routine biopsy specimens are taken from the antrum and corpus, at least two biopsies from each. These biopsies are taken from the large and small curvature of the middle antrum (biopsies 1 and 4) and from the large curvature of the corpus (biopsies 5 and 6). In addition, two extra biopsies are recommended to be taken from the incisura

angularis (biopsies 2 and 3). Importantly, to facilitate the pathology reading, the biopsies from the antrum and incisura (Biopsies 1, 2, 3 and 4) must be immersed into one and the same formalin bottle, and embedded into the same paraffin block (Block No. 1; labeled **ANTRUM**). The two biopsies from the corpus are set into one and the same formalin tube, and embedded into the same paraffin block (Block No. 2; labeled **CORPUS**). In addition, biopsies from the bulb and the second part of the duodenum, distal and mid esophagus will be taken.

3.4.2. Interpretation of the biopsies

All gastroscopy biopsies are examined by the expert pathologists as part of their daily routine at the Department of Pathology, Hospital X. The diagnoses are reported using the USS for classification of gastritis, and diagnosed into different “phenotypes” of gastritis (97,100,101,102,103).

3.5. Statistical analyses

All statistical analyses will be performed using the SPSS 23.0.0.1 for Windows (IBM, NY, USA) and STATA/SE 14.1 software (STATA Corp., Texas, USA). The descriptive statistics will be done according to routine procedures. Performance indicators (sensitivity, specificity, positive predictive value, PPV, negative predictive value, NPV and their 95%CI) of individual markers and whole GastroPanel® test will be calculated separately for each study endpoint, using the STATA/SE software and the *diagti* algorithm introduced by Seed et al. (2001)(107). This algorithm also calculates the area under ROC (Receiver Operating Characteristics) called AUC, for each biomarker at each endpoint. Because GastroPanel® is a quantitative ELISA test, these ROC curves can be used to identify the optimal sensitivity/specificity balance that gives each biomarker an optimal threshold for detection of each study endpoint. Significance of the difference between AUC values can be estimated using STATA’s *roccomb* test with 95%CI.

4. ETHICAL ISSUES

The study design and its execution does not involve any significant ethical issues except those in other clinical studies of similar type. The study protocol will be submitted for approval to the Regional Ethical Committee (Hospital X), and the study is conducted in accordance with the Declaration of Helsinki.

Patients are enrolled among consecutive DM1 patients attending the outpatient department of Hospital X for the scheduled appointment to control their disease. Thus, they represent regular DM1 outpatients controlled in the hospital as part of their routine clinical surveillance for DM1. The only additional procedures carried out to the patients include filling of questionnaires and the blood sampling. The maximum amount of venous blood taken is 10 ml. All patients must sign the informed consent for their participation. When the result of the GastroPanel® test is available, clinical judgement is used to make the referral for gastroscopy. Based on existing clinical practice, however, any patient with suspected AG/AAG needs gastroscopic confirmation of the disease severity (5,97). In this respect, the study protocol does not include any diagnostic procedure additional to the existing clinical practices. Once all results are available, the patients will be informed about the results, following the usual clinical practices, including an explanation of the test results and the appropriate measures for further conduct.

5. TIME FRAME

Given that the subjects in the study will be enrolled among consecutive DM1 patients with estimated 10-15% prevalence of AAG/PA, attending the ambulatory of Hospital X, (with attendance rate of **X? patients/week**), and a cohort of patients enriched with sufficient numbers of all study endpoints will be needed, it is estimated that GastroPanel screening of a minimum of 1000 subjects will take **approximately ? months** of clinical work. The laboratory arm of this study is expected to proceed online with the progress of patient enrollment and gastroscopies. Despite a minor delay (of days) due to the biopsy examination by the pathologists, the full database of the patients will be ready for statistical analysis practically on real-time after completion of the enrollment of the cohort and examination of their blood and biopsy samples.

6. PROJECTED COSTS TO BE COVERED by Biohit Oyj

The company will compensate the extra effort put in the project by Hospital X. The details are subject to discussions and contractual agreement.

REFERENCES

1. Whittingham S, Mackay IR. Pernicious anemia and gastric atrophy. In: Rose NR, Mackay IR, eds. *The autoimmune diseases*. New York: Academic Press; 1985; 243–266.
2. Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. *Clin Immunol Immunopathol* 1997; 84:223–243.
3. Carmel R. Prevalence of undiagnosed pernicious anemia in the elderly. *Arch Intern Med* 1996;156:1097–1100.
4. Riley WJ, Toskes PP, Maclaren NK, Silverstein J. Predictive value of gastric parietal cell autoantibodies as a marker for gastric and hematologic abnormalities associated with insulin dependent diabetes. *Diabetes* 1982;31:1051–1055.
5. De Block CEM, De Leeuw IH, Van Gaal LF. Autoimmune Gastritis in Type 1 Diabetes: A Clinically Oriented Review. *J Clin Endocrinol Metab* 2008;93:363–371.
6. Centanni M, Marignani M, Gargano L, Corleto VD, Casini A, Delle Fave G, Andreoli M, Annibale B. Atrophic body gastritis in patients with autoimmune thyroid disease. An underdiagnosed association. *Arch Intern Med* 1999;159:1726–1730.
7. Irvine WJ, Scarth L, Clarke BF, Cullen R, Duncan LJP. Thyroid and gastric autoimmunity in patients with diabetes mellitus. *Lancet* 1970;2:163–168.
8. Strickland RG, Mackay I. A reappraisal of the nature and significance of chronic atrophic gastritis. *Am J Dig Dis* 1973;18:426–440.
9. Marignani M, Delle Fave G, Mecarocci S, Bordi C, Angeletti S, D'Ambra G, Aprile MMR, Corleto VD, Monarca B, Annibale B. High prevalence of atrophic body gastritis in patients with unexplained microcytic and macrocytic anemia. *Am J Gastroenterol* 1999;94:766–772.
10. De Block CE, Van Campenhout CM, De Leeuw IH, Keenoy BM, Martin M, Van Hoof V, Van Gaal LF. Soluble transferrin receptor level: a new marker of iron deficiency anemia, a common manifestation of gastric autoimmunity in type 1 diabetes. *Diabetes Care* 2000;23:1384–1388.
11. Kokkola A, Sjöblom SM, Haapiainen R, Sipponen P, Puolakainen P, Järvinen H. The risk of gastric carcinoma and carcinoid tumours in patients with pernicious anaemia: a prospective follow-up study. *Scand J Gastroenterol* 1998;33:88–92.
12. Addison T. Anaemia: disease of the suprarenal capsules. *London Med Gaz* 1849; 8:517–518.
13. Flint A. A clinical lecture on anaemia, delivered at the Long Island College Hospital. *American Medical Times* 1860;1:181–186.
14. Castle WB. Development of knowledge concerning the gastric intrinsic factor and its relation to pernicious anemia. *N Engl J Med* 1953;249:603–614.
15. Schwartz M. Intrinsic factor antibody in serum from patients with pernicious anaemia. *Lancet* 1960;2:1263–1267.
16. Irvine WJ, Davies SH, Delamore IW, Williams AW. Immunological relationship between pernicious anemia and thyroid disease. *Br J Med* 1962;2:454–456.
17. Irvine W. Immunologic aspects of pernicious anemia. *N Engl J Med* 1965;273:432–438.
18. Kaye MD. Immunological aspects of gastritis and pernicious anaemia. *Baillieres Clin Gastroenterol* 1987;1:487–506.
19. Toh BH, Van Driel IR, Gleeson PA. Mechanisms of disease: pernicious anemia. *N Engl J Med* 1997;337:1441–1448.
20. Varis K, Kekki M, Härkönen M, Sipponen P, Samloff IM. Serum pepsinogen I and serum gastrin in the screening of atrophic pangastritis with high risk of gastric cancer. *Scand J Gastroenterol Suppl* 1991;186:117–123.
21. De Block C, De Leeuw I, Bogers J, Pelckmans P, Ieven M, Van Marck E, Van Acker K, Van Gaal L. Autoimmune gastropathy in type 1 diabetic patients with parietal cell antibodies: histological and clinical findings. *Diabetes Care* 2003;26:82–88.

- 22.Solcia E, Fiocca T, Villani L, Gianatti A, Cornaggia M, Chiaravalli A, Curzio M, Capella C. Morphology and pathogenesis of endocrine hyperplasias, precarcinoid lesions, and carcinoids arising in chronic atrophic gastritis. *Scand J Gastroenterol Suppl* 1991;180:146–159.
- 23.Fisher JM, Taylor KB. A comparison of autoimmune phenomena in pernicious anemia and chronic atrophic gastritis. *N Engl J Med* 1965;272:499–503.
- 24.Karlsson FA, Burman P, Löf L, Olsson M, Scheynius A, Mardh S. Enzyme linked immunosorbent assay of H⁺/K⁺ ATPase, the parietal cell antigen. *Clin Exp Immunol* 1987;70:604–610.
- 25.Taylor KB, Roitt IM, Doniach D, Couchman KG, Shapland C. Autoimmune phenomena in pernicious anemia: gastric antibodies. *Br Med J* 1962;2:1347–1352.
- 26.Perasso A, Testino G, de'Angelis P, Augeri C, de Grandi R. Gastric chief cell mass in chronic gastritis. Count and relationships to parietal cell mass and functional indices. *Hepatogastroenterology* 1990;38 (Suppl 1):63–66.
- 27.Burman P, Mardh S, Norberg L, Karlsson FA. Parietal cell antibodies in pernicious anemia inhibit H⁺, K⁺ adenosine triphosphatase, the proton pump of the stomach. *Gastroenterology* 1989;96:1434–1438.
- 28.Trudeau WL, McGuigan JE. Relations between serum gastrin levels and rates of gastric hydrochloric acid secretion. *N Engl J Med* 1971;284:408–412.
- 29.Sipponen P, Valle J, Varis K, Kekki M, Ihamäki T, Siurala M. Fasting levels of serum gastrin in different functional and morphologic states of the antrofundal mucosa. An analysis of 860 subjects. *Scand J Gastroenterol* 1990;25:513–519.
- 30.Samloff IM, Varis K, Ihamaki T, Siurala M, Rotter JI. Relationships among serum pepsinogen I, serum pepsinogen II, and gastric mucosal histology. A study in relatives of patients with pernicious anemia. *Gastroenterol* 1982;83:204–209.
- 31.Alonso N, Granada ML, Salinas I, Lucas AM, Reverter JL, Junca J, Oriol A, Sanmarti A. Serum pepsinogen I an early marker of pernicious anemia in patients with type 1 diabetes. *J Clin Endocrinol Metab* 2005;90:5254–5258.
- 32.Armbrrecht U, Stockbrügger RW, Rode J, Menon GG, Cotton PB 1990 Development of gastric dysplasia in pernicious anaemia: a clinical and endoscopic follow-up study of 80 patients. *Gut* 31:1105–1109.
- 33.Borch K, Renvall H, Liedberg G. Gastric endocrine cell hyperplasia and carcinoid tumors in pernicious anemia. *Gastroenterology* 1985;88:638–648.
- 34.Sjöblom SM, Sipponen P, Järvinen H. Gastroscopic follow-up of pernicious anaemia patients. *Gut* 1993;34:28–32.
- 35.Maclaren NK, Riley WJ. Thyroid, gastric, and adrenal autoimmunities associated with insulin-dependent diabetes mellitus. *Diabetes Care* 1985; 8 (Suppl1):34–38.
- 36.Betterle C, Zanette F, Pedini B, Presoto F, Rapp LB, Monciotto CM, Rigon F. Clinical and subclinical organ-specific autoimmune manifestations in type 1 (insulin-dependent) diabetic patients and their first-degree relatives. *Diabetologia* 1984;26:431–436.
- 37.Landin-Olsson M, Karlsson FA, Lernmark A, Sundkvist G. Islet cell and thyrogastic antibodies in 633 consecutive 15- to 34-yr-old patients in the diabetes incidence study in Sweden. *Diabetes* 1992;41:1022–1027.
- 38.Betterle C, Mazzi PA, Pedini B, Accordi F, Cecchetto A, Presotto F. Complement-fixing gastric parietal cell autoantibodies. A good marker for the identification of type A chronic atrophic gastritis. *Autoimmunity* 1988;1:267–274.
- 39.Oksanen A, Sipponen P, Karttunen R, Miettinen A, Veijola L, Sarna S, Rautelin H. Atrophic gastritis and *Helicobacter pylori* infection in outpatients referred for gastroscopy. *Gut* 2000;46:460–463.
- 40.Ungar B, Stocks AE, Whittingham S, Martin FIR, Mackay IR. Intrinsic factor antibody, parietal-cell antibody, and latent pernicious anaemia in diabetes mellitus. *Lancet* 1968;2:415–417.
- 41.De Block CE, De Leeuw IH, Vertommen JJ, Rooman RP, Du Caju MV, Van Campenhout CM, Weyler JJ, Winnock F, Van Autreve J, Gorus FK, Belgian Diabetes Registry. β -cell, thyroid, gastric, adrenal and coeliac autoimmunity and HLA-DQ types in type 1 diabetes. *Clin Exp Immunol* 2001;126:236–241.
- 42.Annibale B, Capurso G, Delle Fave G. The stomach and iron deficiency anaemia: a forgotten link. *Dig Liver Dis* 2003;35:288–295.

43. Toh BH, Alderuccio F. Pernicious anaemia. *Autoimmunity* 2004;37:357–361.
44. Irvine WJ, Cullen DR, Mawhinney H. Natural history of autoimmune achlorhydric atrophic gastritis. *Lancet* 1974;2:482–485.
45. Kaplan LM, Graeme-Cook FM. Case records of the Massachusetts General Hospital (Case 9–1997). A 39 year-old woman with pernicious anemia and a gastric mass. *N Engl J Med* 1997;336:861–867.
46. Hsing A, Hansson L, McLaughlin J, Nyren O, Blot W, Ekblom A, Fraumeni Jr JF. Pernicious anemia and subsequent cancer: a population-based cohort study. *Cancer* 1993;71:745–750.
47. Brinton L, Gridley G, Hrubec Z, Hoover R, Fraumeni Jr JF. Cancer risk following pernicious anaemia. *Br J Cancer* 1989;59:810–813.
48. Carpenter C, Patalas E. Case records of the Massachusetts General Hospital (Case 40–2000): a 38-year-old woman with gastric adenocarcinoma. *N Engl J Med* 2000;343:1951–1958.
49. Karlsson FA, Burman P, Löf L, Mardh S. Major parietal cell antigen in autoimmune gastritis with pernicious anemia is the acid-producing H⁺, K⁺-adenosine triphosphatase of the stomach. *J Clin Invest* 1988;81:475–479.
50. Toh BH, Sentry JW, Alderuccio F. The causative H⁺/K⁺ ATPase antigen in the pathogenesis of autoimmune gastritis. *Immunol Today* 2000;21:348–354.
51. van Driel IR, Baxter AG, Laurie KL, Zwar TD, La Gruta NL, Judd LM, Scarff KL, Silveira PA, Gleeson PA. Immunopathogenesis, loss of T cell tolerance and genetics of autoimmune gastritis. *Autoimmun Rev* 2002;1:290–297.
52. Appelmelk B, Faller G, Claeys D, Kirchner T, Van den Broucke-Grauls C. Bugs on trial: the case of *Helicobacter pylori* and autoimmunity. *Immunol Today* 1998;19:296–299.
53. Amedei A, Bergman MP, Appelmelk BJ, Azzurri A, Benagiano M, Tamburini C, van der Zee R, Telford JL, Vandembroucke-Grauls CM, D'Elis MM, Del Prete G. Molecular mimicry between *Helicobacter pylori* antigens and H⁺, K⁺-adenosine triphosphatase in human gastric autoimmunity. *J Exp Med* 2003;198:1147–1156.
54. van Driel IR, Read S, Zwar T, Gleeson PA. Shaping the T cell repertoire to a bona fide autoantigen: lessons from autoimmune gastritis. *Curr Opin Immunol* 2005;17:570–576.
55. D'Elis MM, Appelmelk BJ, Amedei A, Bergman MP, Del Prete GF. Gastric autoimmunity: the role of *Helicobacter pylori* and molecular mimicry. *Trends Mol Med* 2004;10:316–323.
56. Lam-Tse WK, Batstra MR, Koeleman BP, Roep BO, Bruining MG, Aanstoot HJ, Drexhage HA. The association between autoimmune thyroiditis, autoimmune gastritis and type 1 diabetes. *Pediatr Endocrinol Rev* 2003; 1:22–37.
57. Betterle C, Dal Pra C, Mantero F, Zanchetta R. Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction. *Endocr Rev* 2002;23:327–364.
58. Doniach D, Roitt IM, Taylor KB. Autoimmune phenomena in pernicious anaemia: serological overlap with thyroiditis, thyrotoxicosis and systemic lupus erythematosus. *Br Med J* 1963;1:1374–1379.
59. De Block CE, De Leeuw IH, Rooman RP, Winnock F, Du Caju MV, Van Gaal LF. Gastric parietal cell antibodies are associated with glutamic acid decarboxylase-65 antibodies and the HLA DQA1*0501-DQB1*0301 haplotype in Type 1 diabetes mellitus. *Belgian Diabetes Registry. Diabet Med* 2000;17:618–622.
60. De Block CE, De Leeuw IH, Decochez K, Winnock F, Van Autreve J, Van Campenhout CM, Martin M, Gorus FK, Belgian Diabetes Registry. The presence of thyrogastric antibodies in first-degree relatives of type 1 diabetic patients is associated with age and proband antibody status. *J Clin Endocrinol Metab* 2001;86:4358–4363.
61. Karnes Jr WE, Samloff IM, Siurala M, Kekki M, Sipponen P, Kim SW, Walsh JH. Positive serum antibody and negative tissue staining for *Helicobacter pylori* in subject with atrophic body gastritis. *Gastroenterol* 1991;101:167–174.
62. Fong TL, Dooley CP, Dehesa M, Cohen H, Carmel R, Fitzgibbons PL, Perez-Perez GI, Blaser MJ. *Helicobacter pylori* infection in pernicious anemia: a prospective controlled study. *Gastroenterol* 1991;100:328–332.
63. Ma JY, Borch K, Sjöstrand SE, Janzon L, Mardh S. Positive correlation between H⁺,K⁺-adenosine triphosphatase autoantibodies and *Helicobacter pylori* antibodies in patients with pernicious anemia. *Scand J Gastroenterol* 1994;29:961–965.

64. Annibale B, Aprile MR, D'ambra G, Caruana P, Bordi C, Delle Fave G. Cure of *Helicobacter pylori* infection in atrophic body gastritis patients does not improve mucosal atrophy but reduces hypergastrinemia and its related effects on body ECL-cell hyperplasia. *Aliment Pharmacol Ther* 2000;14:625–634.
65. Uibo R, Vorobjova T, Metsküla K, Kisand K, Wadström T, Kivik T. Association of *Helicobacter pylori* and gastric autoimmunity: a population-based study. *FEMS Immunol Med Microbiol* 1995;11:65–68.
66. Negrini R, Savio A, Poiesi C, Appelmelk B, Buffoli F, Paterlini A, Cesari P, Graffeo M, Vaira D, Franzin G. Antigenic mimicry between *Helicobacter pylori* and gastric mucosa in the pathogenesis of body atrophic gastritis. *Gastroenterol* 1996;111:655–665.
67. Faller G, Steiniger H, Kränzlein J, Maul H, Kerkau T, Hensen J, Hahn EG, Kirchner T. Antigastric autoantibodies in *Helicobacter pylori* infection: implications of histological and clinical parameters of gastritis. *Gut* 1997;41:619–623.
68. Claeys D, Faller G, Appelmelk BJ, Negrini R, Kirchner T. The gastric H/K ATPase is a major autoantigen in chronic *Helicobacter pylori* gastritis with body mucosa atrophy. *Gastroenterology* 1998; 115:340–347.
69. Kohlstadt IC, Antunez De Mayolo EA. Parietal cell antibodies among Peruvians with gastric pathology changes. *Scand J Gastroenterol* 1993;28:973–977.
70. De Block CEM, De Leeuw IH, Bogers JJPM, Pelckmans PA, Ieven M, Van Marck EAE, Van Hoof V, Ma'day E, Van Acker KL, Van Gaal LF. *Helicobacter pylori*, parietal cell antibodies and autoimmune gastropathy in type 1 diabetes mellitus. *Aliment Pharmacol Ther* 2002;16:281–289.
71. Villako K, Kekki M, Maaros HI, Sipponen P, Tammur R, Tamm A, Keevallik R. A 12-year follow-up study of chronic gastritis and *Helicobacter pylori* in a population-based random sample. *Scand J Gastroenterol* 1995;30:964–967.
72. Faller G, Winter M, Steininger H, Lehn N, Meining A, Bayerdorffer E, Kirchner T. Decrease of antigastric autoantibodies in *Helicobacter pylori* gastritis after cure of infection. *Pathol Res Pract* 1999;195:243–246.
73. Sipponen P, Kekki M, Haapakoski J, Ihamäki T, Siurala M. Gastric cancer risk in chronic atrophic gastritis: statistical calculations of cross-sectional data. *Int J Cancer* 1985;35:173–177.
74. Correa P, Haenszel W, Cuello C, Zavala D, Fontham E, Zarama G. Gastric precancerous process in a high risk population: cohort follow-up. *Cancer Res* 1990;50:4737–4740.
75. Filipe MI, Munoz N, Matko I, Kato I, Pompe-Kirn V, Jutersek A. Intestinal metaplasia types and the risk of gastric cancer: a cohort study in Slovenia. *Int J Cancer* 1994;57:324–329.
76. Ohata H, Kitauchi S, Yoshimura N, Mugitani K, Iwane M, Nakamura H. Progression of chronic atrophic gastritis associated with *Helicobacter pylori* infection increases risk of gastric cancer. *Int J Cancer* 2004;109: 138–143.
77. Correa P. A human model of gastric carcinogenesis. *Cancer Res* 1988;48:3554–3560.
78. Correa P. The epidemiology of gastric cancer. *World J Surg* 1991;15:228–234.
79. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process – First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. *Cancer Res* 1992;52:6735–6740.
80. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ. European *Helicobacter* Study Group. Management of *Helicobacter pylori* infection--the Maastricht IV/ Florence Consensus Report. *Gut* 2012;61: 646–664.
81. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M. *Helicobacter pylori* infection and the development of gastric cancer. *N Engl J Med* 2001;345:829–832.
82. Weck MN, Stegmaier C, Rothenbacher D, Brenner H. Epidemiology of chronic atrophic gastritis: population-based study among 9444 older adults from Germany. *Aliment Pharmacol Ther* 2007;26: 879–887.
83. Lomba-Viana R, Dinis-Ribeiro M, Fonseca F, Vieira AS, Bento MJ, Lomba-Viana H. Serum pepsinogen test for early detection of gastric cancer in a European country. *Eur J Gastroenterol Hepatol* 2012;24:37–41.
84. Bornschein J, Selgrad M, Wex T, Kuester D, Malfertheiner P. Serological assessment of gastric mucosal atrophy in gastric cancer. *BMC Gastroenterol* 2012;12:10. doi: 10.1186/1471-230X-12-10.
85. Valle J, Kekki M, Sipponen P, Ihamäki T, Siurala M. Longterm course and consequences of *Helicobacter pylori* gastritis. Results of a 32-year follow-up study. *Scand J Gastroenterol* 1996;31:546–550.

- 86.Germaná B, Di Mario F, Cavallaro LG, Moussa AM, Lecis P, Liatoupolou S, Comparato G, Carloni C, Bertiato G, Battiestel M, Papa N, Aragona G, Cavestro GM, Iori V, Merli R, Bertolini S, Caruana P, Franzé A. Clinical usefulness of serum pepsinogens I and II, gastrin-17 and anti-Helicobacterpylori antibodies in the management of dyspeptic patients in primary care. *Dig Liver Dis* 2005;37:501-508.
- 87.Miki K, Ichinose M, Shimizu A, Huang SC, Oka H, Furihata C, Matsushima T, Takahashi K. Serum pepsinogens as a screening test of extensive chronic gastritis. *Gastroenterol Jpn* 1987;22:133-141.
- 88.Samloff IM, Varis K, Ihamaki T, Siurala M, Rotter JI. Relationships among serum pepsinogen I, serum pepsinogen II, and gastric mucosal histology. A study in relatives of patients with pernicious anemia. *Gastroenterol* 1982;83:204-209.
- 89.Korstanje A, den Hartog G, Biemond I, Lamers CB. The serological gastric biopsy: a non-endoscopic diagnostic approach in management of the dyspeptic patient: significance for primary care based on a survey of the literature. *Scand J Gastroenterol Suppl* 2002;236:22-26.
- 90.Oksanen A, Sipponen P, Miettinen A, Sarna S, Rautelin H. Evaluation of blood tests to normal gastric mucosa. *Scand J Gastroenterol* 2000;35:791-795.
- 91.Varis K, Sipponen P, Laxen F, Samloff IM, Huttunen JK, Taylor PR, The Helsinki Gastritis Study Group. Implications of serum pepsinogen I in early endoscopic diagnosis of gastric cancer and dysplasia. *Scand J Gastroenterol* 2000;35:950-956.
- 92.Miki K. Gastric cancer screening using the serum pepsinogen test method. *Gastric Cancer* 2006;9:245-253.
- 93.Agréus L, Kuipers EJ, Kupcinskis L, Malfertheiner P, Di Mario F, Leja M, Mahachai V, Yaron N, van Oijen M, Perez Perez G, Rugge M, Ronkainen J, Salaspuro M, Sipponen P, Sugano K, Sung J. Rationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers. *Scand J Gastroenterol* 2012;47:136-147.
- 94.Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC: CancerBase No. 9. <http://globocan.iarc.fr>
- 95.Storskrubb T, Aro P, Ronkainen J, Sipponen P, Nyhlin H, Talley NJ. Serum biomarkers provide an accurate method for diagnosis of atrophic gastritis in a general population: the Kalixanda study. *Scand J Gastroenterol* 2008;43:1448-1455.
- 96.Telaranta-Keerie A, Kara R, Paloheimo L, Härkönen M, Sipponen P. Prevalence of undiagnosed advanced atrophic corpus gastritis in Finland: an observational study among 4,256 volunteers without specific complaints. *Scand J Gastroenterol* 2010;45:1036-1041.
- 97.Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. *Am J Surg Pathol* 1996;20: 1161-1181.
- 98.Dinis-Ribeiro M, Yamaki G, Miki K, Costa-Pereira A, Matsukawa M, Kurihara M. Meta-analysis on the validity of pepsinogen test for gastric carcinoma, dysplasia or chronic atrophic gastritis screening. *J Med Screen* 2004;11:141-147.
- 99.Varis K, Isokoski M. Screening of type A gastritis. *Ann Clin Res* 1981;13:133-138.
- 100.Sipponen P, Valle J, Varis K, Kekki M, Ihamäki T, Siurala M. Fasting levels of serum gastrin in different functional and morphologic states of the antrofundal mucosa. An analysis of 860 subjects. *Scand J Gastroenterol* 1990;25:513-519.
- 101.Varis K, Kekki M, Härkönen M, Sipponen P, Samloff IM. Serum pepsinogen I and serum gastrin in the screening of atrophic pangastritis with high risk of gastric cancer. *Scand J Gastroenterol* 1991;186:117-123.
- 102.Sipponen P, Ranta P, Helske T, Kääriäinen I, Mäki T, Linnala A. Serum levels of amidated gastrin-17 and pepsinogen I in atrophic gastritis: an observational case-control study. *Scand J Gastroenterol* 2002;37:785-791.
- 103.Väänänen H, Vauhkonen M, Helske T. Non-endoscopic diagnosis of atrophic gastritis with a blood test. Correlation between gastric histology and serum levels of gastrin-17 and pepsinogen I: a multicentre study. *Eur J Gastroenterol Hepatol* 2003;15:885-891.
- 104.Benberin V, Bektayeva R, Karabayeva R. Prevalence of H.pylori infection and atrophic gastritis among symptomatic and dyspeptic adults in Kazakhstan. A hospital-based screening with a panel of serum biomarkers. *Anticancer Res* 2013;33:4595-4602.

- 105.Syrjänen KJ, Sipponen P, Härkönen M, Peetsalu A, Korpela S. Accuracy of GastroPanel testing in detection of atrophic gastritis. *Eur J Gastroenterol Hepatol* 2015;27:102-104.
- 106.Aro P, Ronkainen J, Storskrubb T, Bolling-Sternevald E, Johansson S-E, Talley NJ. Validation of the translation and cross-cultural adaptation into Finnish of the Abdominal Symptom Questionnaire, the Hospital Anxiety and Depression Scale and the Complaint Score Questionnaire. *Scand J Gastroenterol* 2004;39:1201-1208.
- 107.Seed PT, Tobias A. Summary statistics for diagnostic tests. *Stata Techn Bull* 2001;59:9-12.